{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:12:18Z","timestamp":1788930738830,"version":"build-2803163510"},"posted":{"date-parts":[[2024,1,8]]},"group-title":"In Review","reference-count":58,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,12,20]]},"abstract":"<title>Abstract<\/title><p><bold>Objective:<\/bold>The use of blood-based biomarkers of Alzheimer disease (AD) may facilitate access to biomarker testing of groups that have been historically under-represented in research. We evaluated whether plasma A\u03b242\/40 has similar or different baseline levels and longitudinal rates of change in participants racialized as Black or White.<bold>Methods:<\/bold>The Study of Race to Understand Alzheimer Biomarkers (SORTOUT-AB) is a multi-center longitudinal study to evaluate for potential differences in AD biomarkers between individuals racialized as Black or White. Plasma samples collected at three AD Research Centers (Washington University, University of Pennsylvania, and University of Alabama-Birmingham) underwent analysis with C<sub>2<\/sub>N Diagnostics\u2019 PrecivityAD\u2122 blood test for A\u03b242 and A\u03b240. General linear mixed effects models were used to estimate the baseline levels and rates of longitudinal change for plasma A\u03b2 measures in both racial groups. Analyses also examined whether dementia status, age, sex, education,<italic>APOE<\/italic><italic>\u03b5<\/italic>4 carrier status, medical comorbidities, or fasting status modified potential racial differences.<bold>Results:<\/bold>Of the 324 Black and 1,547 White participants, there were 158 Black and 759 White participants with plasma A\u03b2 measures from at least two longitudinal samples over a mean interval of 6.62 years. At baseline, the group of Black participants had lower levels of plasma A\u03b240 but similar levels of plasma A\u03b242 as compared to the group of White participants. As a result, baseline plasma A\u03b242\/40 levels were higher in the Black group than the White group, consistent with the Black group having lower levels of amyloid pathology. Racial differences in plasma A\u03b242\/40 were not modified by age, sex, education,<italic>APOE<\/italic><italic>\u03b5<\/italic>4 carrier status, medical conditions (hypertension and diabetes), or fasting status. Despite differences in baseline levels, the Black and White groups had a similar longitudinal rate of change in plasma A\u03b242\/40.<bold>Interpretation:<\/bold>Black individuals participating in AD research studies had a higher mean level of plasma A\u03b242\/40, consistent with a lower level of amyloid pathology, which, if confirmed, may imply a lower proportion of Black individuals being eligible for AD clinical trials in which the presence of amyloid is a prerequisite. However, there was no significant racial difference in the rate of change in plasma A\u03b242\/40, suggesting that amyloid pathology accumulates similarly across racialized groups.<\/p>","DOI":"10.21203\/rs.3.rs-3783571\/v1","type":"posted-content","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T17:34:53Z","timestamp":1704735293000},"source":"Crossref","is-referenced-by-count":10,"title":["Baseline levels and longitudinal rates of change in plasma A\u03b242\/40 among self-identified Black\/African American and White individuals"],"prefix":"10.21203","author":[{"given":"Chengjie","family":"Xiong","sequence":"first","affiliation":[{"name":"Washington University in St. Louis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Schindler","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2759-3072","authenticated-orcid":false,"given":"Jingqin","family":"Luo","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Morris","sequence":"additional","affiliation":[{"name":"Knight Alzheimer Disease Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7729-1702","authenticated-orcid":false,"given":"Randall","family":"Bateman","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3400-0856","authenticated-orcid":false,"given":"David","family":"Holtzman","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0276-2899","authenticated-orcid":false,"given":"Carlos","family":"Cruchaga","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Babulal","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Henson","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8114-0552","authenticated-orcid":false,"given":"Tammie","family":"Benzinger","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quoc","family":"Bui","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folasade","family":"Agboola","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Grant","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Gremminger","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Moulder","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Geldmacher","sequence":"additional","affiliation":[{"name":"University of Alabama Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivio","family":"Clay","sequence":"additional","affiliation":[{"name":"University of Alabama Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1810-9763","authenticated-orcid":false,"given":"Erik","family":"Roberson","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Murchison","sequence":"additional","affiliation":[{"name":"University of Alabama Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wolk","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Shaw","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s43587-023-00400-6","article-title":"The role of cerebrospinal fluid and other biomarker modalities in the Alzheimer's disease diagnostic revolution","volume":"3","author":"Schindler SE","year":"2023","unstructured":"Schindler SE, Atri A (2023) The role of cerebrospinal fluid and other biomarker modalities in the Alzheimer's disease diagnostic revolution. Nat Aging 3(5):460\u2013462","journal-title":"Nat Aging"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s43587-023-00410-4","article-title":"Detection and treatment of Alzheimer's disease in its preclinical stage","volume":"3","author":"Rafii MS","year":"2023","unstructured":"Rafii MS, Aisen PS (2023) Detection and treatment of Alzheimer's disease in its preclinical stage. Nat Aging 3(5):520\u2013531","journal-title":"Nat Aging"},{"issue":"1","key":"ref3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41380-020-0721-9","article-title":"Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies","volume":"26","author":"Zetterberg H","unstructured":"Zetterberg H, Bendlin BB (2021 Jan) Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies. Mol Psychiatry 26(1):296\u2013308. 10.1038\/s41380-020-0721-9Epub 2020 Apr 6. PMID: 32251378","journal-title":"Mol Psychiatry"},{"key":"ref4","article-title":"Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape","volume":"5","author":"Hampel H","year":"2023","unstructured":"Hampel H, Hu Y, Cummings J et al (2023) Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape. Neuron. Jun 5","journal-title":"Neuron"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer's disease in clinical practice and trials","volume":"3","author":"Hansson O","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J (2023) Blood biomarkers for Alzheimer's disease in clinical practice and trials. Nat Aging 3(5):506\u2013519","journal-title":"Nat Aging"},{"key":"ref6","author":"Karikari TK","year":"2022","unstructured":"Karikari TK (2022) Blood Tests for Alzheimer's Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance. Journal of Alzheimer's disease: JAD. Apr 23"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2018.09.009","article-title":"O'Bryant SE; International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association. Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need","volume":"15","author":"Babulal GM","year":"2019","unstructured":"Babulal GM, Quiroz YT, Albensi BC, Arenaza-Urquijo E, Astell AJ, Babiloni C, Bahar-Fuchs A, Bell J, Bowman GL, Brickman AM, Ch\u00e9telat G, Ciro C, Cohen AD, Dilworth-Anderson P, Dodge HH, Dreux S, Edland S, Esbensen A, Evered L, Ewers M, Fargo KN, Fortea J, Gonzalez H, Gustafson DR, Head E, Hendrix JA, Hofer SM, Johnson LA, Jutten R, Kilborn K, Lanct\u00f4t KL, Manly JJ, Martins RN, Mielke MM, Morris MC, Murray ME, Oh ES, Parra MA, Rissman RA, Roe CM, Santos OA, Scarmeas N, Schneider LS, Schupf N, Sikkes S, Snyder HM, Sohrabi HR, Stern Y, Strydom A, Tang Y, Terrera GM, Teunissen C, van Melo D, Weinborn M, Wesselman L, Wilcock DM, Zetterberg H (2019) O'Bryant SE; International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association. Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimers Dement 15(2):292\u2013312","journal-title":"Alzheimers Dement"},{"issue":"7","key":"ref8","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1002\/alz.13027","article-title":"The structural and social determinants of Alzheimer's disease related dementias","volume":"19","author":"Adkins-Jackson PB","year":"2023","unstructured":"Adkins-Jackson PB, George KM, Besser LM, Hyun J, Lamar M, Hill-Jarrett TG, Bubu OM, Flatt JD, Heyn PC, Cicero EC, Zarina Kraal A, Pushpalata Zanwar P, Peterson R, Kim B, Turner RW 2nd, Viswanathan J, Kulick ER, Zuelsdorff M, Stites SD, Arce Renter\u00eda M, Tsoy E, Seblova D, Ng TKS, Manly JJ, Babulal G (2023) The structural and social determinants of Alzheimer's disease related dementias. Alzheimers Dement 19(7):3171\u20133185","journal-title":"Alzheimers Dement"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fnagi.2016.00296","article-title":"Research Lumbar Punctures among African Americans and Caucasians: Perception Predicts Experience","volume":"8","author":"Howell JC","year":"2016","unstructured":"Howell JC, Parker MW, Watts KD, Kollhoff A, Tsvetkova DZ, Hu WT (2016) Research Lumbar Punctures among African Americans and Caucasians: Perception Predicts Experience. Front Aging Neurosci 8:296","journal-title":"Front Aging Neurosci"},{"issue":"14","key":"ref10","doi-asserted-by":"crossref","first-page":"e1424","DOI":"10.1212\/WNL.0000000000207674","article-title":"Association Between Socioeconomic Factors, Race, and Use of a Specialty Memory Clinic","volume":"101","author":"Lewis A","year":"2023","unstructured":"Lewis A, Gupta A, Oh I et al (2023) Association Between Socioeconomic Factors, Race, and Use of a Specialty Memory Clinic. Neurology 101(14):e1424\u2013e33","journal-title":"Neurology"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jamaneurol.2022.3543","article-title":"Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US: The 2016 Health and Retirement Study Harmonized Cognitive Assessment Protocol Project","volume":"79","author":"Manly JJ","year":"2022","unstructured":"Manly JJ, Jones RN, Langa KM et al (2022) Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US: The 2016 Health and Retirement Study Harmonized Cognitive Assessment Protocol Project. JAMA Neurol 79(12):1242\u20131249","journal-title":"JAMA Neurol"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaneurol.2020.4471","article-title":"Trends in Relative Incidence and Prevalence of Dementia Across Non-Hispanic Black and White Individuals in the United States, 2000\u20132016","volume":"78","author":"Power MC","year":"2021","unstructured":"Power MC, Bennett EE, Turner RW et al (2021) Trends in Relative Incidence and Prevalence of Dementia Across Non-Hispanic Black and White Individuals in the United States, 2000\u20132016. JAMA Neurol 78(3):275\u2013284","journal-title":"JAMA Neurol"},{"issue":"15","key":"ref13","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1001\/jama.2022.3550","article-title":"Association of Race and Ethnicity With Incidence of Dementia Among Older Adults","volume":"327","author":"Kornblith E","year":"2022","unstructured":"Kornblith E, Bahorik A, Boscardin WJ et al (2022) Association of Race and Ethnicity With Incidence of Dementia Among Older Adults. JAMA 327(15):1488\u20131495","journal-title":"JAMA"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/jamaneurol.2022.3157","article-title":"Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort Study","volume":"79","author":"Wilkins CH","year":"2022","unstructured":"Wilkins CH, Windon CC, Dilworth-Anderson P et al (2022) Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort Study. JAMA Neurol 79(11):1139\u20131147","journal-title":"JAMA Neurol"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"e1491","DOI":"10.1212\/WNL.0000000000011599","article-title":"Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study","volume":"96","author":"Deters KD","year":"2021","unstructured":"Deters KD, Napolioni V, Sperling RA et al (2021) Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study. Neurology 96(11):e1491\u2013e500","journal-title":"Neurology"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/jamaneurol.2018.4249","article-title":"Assessment of Racial Disparities in Biomarkers for Alzheimer Disease","volume":"76","author":"Morris JC","year":"2019","unstructured":"Morris JC, Schindler SE, McCue LM et al (2019) Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. JAMA Neurol 76(3):264\u2013273","journal-title":"JAMA Neurol"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13195-017-0315-1","article-title":"Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers","volume":"9","author":"Howell JC","year":"2017","unstructured":"Howell JC, Watts KD, Parker MW et al (2017) Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers. Alzheimers Res Ther 9(1):88","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"e1917363","DOI":"10.1001\/jamanetworkopen.2019.17363","article-title":"Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment","volume":"2","author":"Garrett SL","year":"2019","unstructured":"Garrett SL, McDaniel D, Obideen M et al (2019) Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment. JAMA Netw Open 2(12):e1917363","journal-title":"JAMA Netw Open"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/alz.12608","article-title":"Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults","volume":"18","author":"Xiong C","year":"2022","unstructured":"Xiong C, Luo J, Schindler SE et al (2022) Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults. Alzheimers Dement 18(12):2570\u20132581","journal-title":"Alzheimers Dement"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41582-021-00589-3","article-title":"Alzheimer disease in African American individuals: increased incidence or not enough data?","volume":"18","author":"Barnes LL","year":"2022","unstructured":"Barnes LL (2022) Alzheimer disease in African American individuals: increased incidence or not enough data? Nat Rev Neurol 18:56\u201362","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1212\/WNL.0000000000002914","article-title":"The ARIC-PET amyloid imaging study: Brain amyloid differences by age, race, sex, and APOE","volume":"87","author":"Gottesman RF","year":"2016","unstructured":"Gottesman RF, Schneider AL, Zhou Y et al (2016) The ARIC-PET amyloid imaging study: Brain amyloid differences by age, race, sex, and APOE. Neurology 87(5):473\u2013480","journal-title":"Neurology"},{"key":"ref22","first-page":"21","article-title":"Effect of Race on Prediction of Brain Amyloidosis by Plasma Abeta42\/Abeta40, Phosphorylated Tau, and Neurofilament Light","author":"Schindler SE","year":"2022","unstructured":"Schindler SE, Karikari TK, Ashton NJ et al (2022) Effect of Race on Prediction of Brain Amyloidosis by Plasma Abeta42\/Abeta40, Phosphorylated Tau, and Neurofilament Light. Neurology. Apr 21","journal-title":"Neurology"},{"key":"ref23","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","volume":"26","author":"Mielke MM","year":"2022","unstructured":"Mielke MM, Dage JL, Frank RD et al (2022) Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. May 26","journal-title":"Nat Med"},{"issue":"7","key":"ref24","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-022-01875-3","article-title":"Comorbidities confound Alzheimer's blood tests","volume":"28","author":"Schindler SE","year":"2022","unstructured":"Schindler SE, Karikari TK (2022) Comorbidities confound Alzheimer's blood tests. Nat Med 28(7):1349\u20131351","journal-title":"Nat Med"},{"key":"ref25","first-page":"27","article-title":"Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimer's & dementia: the journal of the Alzheimer's Association","author":"Syrjanen JA","year":"2021","unstructured":"Syrjanen JA, Campbell MR, Algeciras-Schimnich A et al (2021) Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimer's & dementia: the journal of the Alzheimer's Association. Sep 27"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","article-title":"Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios","volume":"80","author":"Janelidze S","year":"2023","unstructured":"Janelidze S, Barthelemy NR, He Y, Bateman RJ, Hansson O (2023) Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios. JAMA Neurol 80(5):516\u2013522","journal-title":"JAMA Neurol"},{"issue":"8","key":"ref27","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/alz.12301","article-title":"Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study","volume":"17","author":"Brickman AM","year":"2021","unstructured":"Brickman AM, Manly JJ, Honig LS et al (2021) Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. Alzheimer's Dement J Alzheimer's Assoc 17(8):1353\u20131364","journal-title":"Alzheimer's Dement J Alzheimer's Assoc"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"e12315","DOI":"10.1002\/dad2.12315","article-title":"Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI","volume":"14","author":"Windon C","year":"2022","unstructured":"Windon C, Iaccarino L, Mundada N et al (2022) Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI. Alzheimer's Dement 14(1):e12315","journal-title":"Alzheimer's Dement"},{"issue":"14","key":"ref29","doi-asserted-by":"crossref","first-page":"e1402","DOI":"10.1212\/WNL.0000000000207675","article-title":"Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort","volume":"101","author":"Ramanan VK","year":"2023","unstructured":"Ramanan VK, Graff-Radford J, Syrjanen J et al (2023) Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort. Neurology 101(14):e1402\u2013e11","journal-title":"Neurology"},{"issue":"10","key":"ref30","doi-asserted-by":"publisher","first-page":"e2235068","DOI":"10.1001\/jamanetworkopen.2022.35068","article-title":"Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors","volume":"5","author":"Hajjar I","year":"2022","unstructured":"Hajjar I, Yang Z, Okafor M et al (2022) Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors. JAMA Netw Open 5(10):e2235068. 10.1001\/jamanetworkopen.2022.35068","journal-title":"JAMA Netw Open"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/acn3.51863","article-title":"A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment","volume":"10","author":"Monane M","year":"2023","unstructured":"Monane M, Johnson KG, Snider BJ et al (2023) A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment. Ann Clin Transl Neurol 10(10):1738\u20131748","journal-title":"Ann Clin Transl Neurol"},{"key":"ref32","first-page":"6","article-title":"Plasma Abeta42\/Abeta40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease","author":"Rissman RA","year":"2023","unstructured":"Rissman RA, Langford O, Raman R et al (2023) Plasma Abeta42\/Abeta40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease. Alzheimer's Dement J Alzheimer's Assoc. Nov 6","journal-title":"Alzheimer's Dement J Alzheimer's Assoc"},{"key":"ref33","author":"Wolk DA","unstructured":"Wolk DA, Mancuso L, Kliot D, Arnold SE, Dickerson BC Familiarity-based memory as an early cognitive marker of preclinical and prodromal AD"},{"key":"ref34","author":"Morris JC","unstructured":"Morris JC, Weintraub S, Chui HC et al (2006 Oct-Dec) Alzheimer Dis Assoc Disord 20(4):210\u2013216The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WAD.0b013e318191c7dd","article-title":"The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery","volume":"23","author":"Weintraub S","unstructured":"Weintraub S, Salmon D, Mercaldo N et al (2009 Apr-Jun) The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord 23(2):91\u2013101","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"11","key":"ref36","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris JC","year":"1993","unstructured":"Morris JC (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43(11):2412\u20132414","journal-title":"Neurology"},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann GM","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement J Alzheimer's Assoc 7(3):263\u2013269","journal-title":"Alzheimer's Dement J Alzheimer's Assoc"},{"issue":"2","key":"ref38","first-page":"134","volume":"30","author":"Monsell SE","unstructured":"Monsell SE, Dodge HH, Zhou XH et al Results From the NACC Uniform Data Set Neuropsychological Battery Crosswalk Study. Alzheimer Dis Assoc Disord 2016 Apr-Jun ;30(2):134\u2013139","journal-title":"Alzheimer Dis Assoc Disord 2016 Apr-Jun"},{"issue":"23","key":"ref39","first-page":"e3104","article-title":"Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study","volume":"95","author":"Luo J","year":"2020","unstructured":"Luo J, Agboola F, Grant E et al (2020) Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study. Neurology 95(23):e3104\u2013e16","journal-title":"Neurology"},{"issue":"4","key":"ref40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects","volume":"65","author":"Shaw LM","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65(4):403\u2013413","journal-title":"Ann Neurol"},{"issue":"4","key":"ref41","doi-asserted-by":"crossref","first-page":"e228392","DOI":"10.1001\/jamanetworkopen.2022.8392","article-title":"Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment","volume":"5","author":"Hu Y","year":"2022","unstructured":"Hu Y, Kirmess KM, Meyer MR et al (2022) Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment. JAMA Netw Open 5(4):e228392","journal-title":"JAMA Netw Open"},{"issue":"9","key":"ref42","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/acn3.50873","article-title":"Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse","volume":"6","author":"Alcolea D","year":"2019","unstructured":"Alcolea D, Pegueroles J, Mu\u00f1oz L et al (2019) Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. Ann Clin Transl Neurol 6(9):1815\u20131824","journal-title":"Ann Clin Transl Neurol"},{"key":"ref43","doi-asserted-by":"crossref","DOI":"10.1038\/s43587-023-00380-7","article-title":"CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer\u2019s disease","author":"Barth\u00e9lemy NR","year":"2023","unstructured":"Barth\u00e9lemy NR, Saef B, Li Y et al (2023) CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer\u2019s disease. Nat Aging. 2023\/03\/13.","journal-title":"Nat Aging"},{"issue":"S5","key":"ref44","doi-asserted-by":"crossref","first-page":"e066912","DOI":"10.1002\/alz.066912","article-title":"A methodology for normalizing fluid biomarker concentrations across reagent lots","volume":"18","author":"Henson RL","year":"2022","unstructured":"Henson RL, Volluz K, Saef BA et al (2022) A methodology for normalizing fluid biomarker concentrations across reagent lots. Alzheimer's Dement 18(S5):e066912","journal-title":"Alzheimer's Dement"},{"issue":"11","key":"ref45","doi-asserted-by":"crossref","first-page":"e73377","DOI":"10.1371\/journal.pone.0073377","article-title":"Quantitative analysis of PiB-PET with FreeSurfer ROIs","volume":"8","author":"Su Y","year":"2013","unstructured":"Su Y, D'Angelo GM, Vlassenko AG et al (2013) Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS ONE 8(11):e73377","journal-title":"PLoS ONE"},{"issue":"5","key":"ref46","first-page":"904","article-title":"Correction for partial volume effects in PET: principle and validation","volume":"39","author":"Rousset OG","year":"1998","unstructured":"Rousset OG, Ma Y, Evans AC (1998) Correction for partial volume effects in PET: principle and validation. J Nucl Med 39(5):904\u2013911","journal-title":"J Nucl Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.nicl.2018.04.022","article-title":"Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies","volume":"19","author":"Su Y","year":"2018","unstructured":"Su Y, Flores S, Hornbeck RC et al (2018) Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. Neuroimage Clin 19:406\u2013416","journal-title":"Neuroimage Clin"},{"issue":"1","key":"ref48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk WE","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC et al (2015) The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer's Dement J Alzheimer's Assoc 11(1):1\u201315e1","journal-title":"Alzheimer's Dement J Alzheimer's Assoc"},{"key":"ref49","volume-title":"Theory and Application of the Linear Model","author":"Graybill FA","year":"1976","unstructured":"Graybill FA (1976) Theory and Application of the Linear Model. Duxbury, North Scituate, Ma"},{"issue":"1","key":"ref50","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini Y","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. J R Stat Soc B 57(1):289\u2013300","journal-title":"J R Stat Soc B"},{"key":"ref51","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198524847.001.0001","volume-title":"Analysis of Longitudinal Data","author":"Diggle PJ","year":"2002","unstructured":"Diggle PJ, Heagerty P, Liang K-Y, Zeger SL (2002) Analysis of Longitudinal Data, 2nd edn. Oxford University Press, New York","edition":"2"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2307\/2529876","article-title":"Random-effects models for longitudinal data","volume":"38","author":"Laird NM","year":"1982","unstructured":"Laird NM, Ware JH (1982) Random-effects models for longitudinal data. Biometrics 38:963\u2013974","journal-title":"Biometrics"},{"key":"ref53","article-title":"Relationships of Cognitive Measures with Cerebrospinal Fluid but not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals","author":"Bonomi S","unstructured":"Bonomi S, Lu R, Schindler SE, Bui Q, Lah JJ, Wolk D, Gleason CE, Sperling R, Roberson ED, Levey AI, Shaw L, Van Hulle C, Benzinger T, Adams M, Manzanares C, Qiu D, Hassenstab J, Moulder KL, Balls-Berry JE, Johnson K, Johnson SC, Murchison C, Luo J, Gremminger E, Agboola F, Grant EA, Hornbeck R, Massoumzadeh P, Keefe S, Dierker D, Gray JD, Henson RL, Streitz M, Mechanic-Hamilton D, Morris JC, Xiong C Relationships of Cognitive Measures with Cerebrospinal Fluid but not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals. Ann Neurol 2023; in press."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"871947","DOI":"10.3389\/fneur.2022.871947","article-title":"Characterizing Plasma Biomarkers of Alzheimer's in a Diverse Community-Based Cohort: A Cross-Sectional Study of the HAB-HD Cohort","volume":"13","author":"Hall JR","year":"2022","unstructured":"Hall JR, Petersen M, Johnson L, O'Bryant SE (2022) Characterizing Plasma Biomarkers of Alzheimer's in a Diverse Community-Based Cohort: A Cross-Sectional Study of the HAB-HD Cohort. Front Neurol 13:871947. 10.3389\/fneur.2022.871947PMID: 36062019; PMCID: PMC9435735","journal-title":"Front Neurol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"e066942","DOI":"10.1002\/alz.066942","article-title":"Trajectories of plasma A\u03b242\/40 among African Americans: Preliminary results from the African American Fighting Alzheimer\u2019s in Midlife (AA-FAIM) study","volume":"18","author":"Hulle CA","year":"2022","unstructured":"Van Hulle CA, Zuelsdorff M, Koscik RL, Ennis GE, Bouges S, Fischer BL, Wyman MF, Lambrou NH, Johnson AL, Umucu E, Salazar H, Chin NA, Meyer MR, Holubasch MS, Kirmess K, Verghese PB, West T, Venkatesh V, Yarasheski KE, Gleason CE (2022) Trajectories of plasma A\u03b242\/40 among African Americans: Preliminary results from the African American Fighting Alzheimer\u2019s in Midlife (AA-FAIM) study. Alzheimer's Dement 18:e066942. https:\/\/doi.org\/10.1002\/alz.066942","journal-title":"Alzheimer's Dement"},{"issue":"9","key":"ref56","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamaneurol.2020.1614","article-title":"Addressing Health Disparities Among Minority Populations: Why Clinical Trial Recruitment Is Not Enough","volume":"77","author":"Wilkins CH","year":"2020","unstructured":"Wilkins CH, Schindler SE, Morris JC (2020) Addressing Health Disparities Among Minority Populations: Why Clinical Trial Recruitment Is Not Enough. JAMA Neurol 77(9):1063\u20131064","journal-title":"JAMA Neurol"},{"key":"ref57","author":"Wilkins CH","unstructured":"Wilkins CH, Schindler SE, Morris JC Fuller, J. T., \u2026 Bettcher, B. M. (2023). Representativeness of samples enrolled in Alzheimer's disease research centers. Alzheimer's & Dementia: Diagnosis, Assessment& Disease Monitoring, 15(2), e12450"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Gilmore-Bykovskyi, A., Croff, R., Glover, C. M., Jackson, J. D., Resendez, J., Perez,A., \u2026 Manly, J. J. (2022). Traversing the aging research and health equity divide:Toward intersectional frameworks of research justice and participation. The Gerontologist,62(5), 711\u2013720","DOI":"10.1093\/geront\/gnab107"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3783571\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3783571\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T18:02:17Z","timestamp":1731002537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3783571\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":58,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-3783571\/v1","relation":{},"subject":[],"published":{"date-parts":[[2024,1,8]]},"subtype":"preprint"}}